Liminal BioSciences Inc. reported earnings results for the second quarter and six months ended June 30, 2023. For the second quarter, the company reported sales was CAD 0.112 million compared to CAD 0.157 million a year ago. Net loss was CAD 9.14 million compared to CAD 6.23 million a year ago. Basic loss per share from continuing operations was CAD 2.89. Basic loss per share was CAD 2.94.
For the six months, sales was CAD 0.248 million compared to CAD 0.157 million a year ago. Net loss was CAD 16.57 million compared to CAD 17.39 million a year ago. Basic loss per share from continuing operations was CAD 5.33. Basic loss per share was CAD 5.34.